Abstracts tagged "Granulomatosis with Polyangiitis (GPA)"

Abstract Number: 0725 • ACR Convergence 2023
Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Sophie Nagle¹, Yann Nguyen², Xavier Puéchal³, Dimitri Titeca-Beauport⁴, Thomas Crépin⁵, Rafik Mesbah⁶, Idris Boudhabhay⁷, Gregory Pugnet⁸, Juliette Woessner⁹, Roderau Outh¹⁰, Céline Lebas¹¹, Antoine Néel¹², alexandre Karras¹³, Eric Hachulla¹¹, Benjamin Subran¹⁴, Philippe Kerschen¹⁵, Mathieu Gerfaud-Valentin¹⁶, Stéphane Vinzio¹⁷, Tiphaine Goulenok¹⁸, Raphael Borie¹⁹, Sébastien Humbert²⁰, Yurdagul Uzunhan²¹, Sarah Melboucy-Belkhir²², Jean-Baptiste Gouin²³, Mary-Jane Guerry²⁴ and Benjamin Terrier²⁵, ¹AP-HP Cochin Hospital, Paris, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ⁴CHU Amiens, Amiens, France, ⁵Amiens University Hospital, Amiens, France, ⁶Boulogne Hospital (CH), Boulogne, France, ⁷Necker University Hospital, Paris, France, ⁸CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ⁹Avignon Hospital (CH), Avignon, France, ¹⁰Perpignan Hospital (CH), Perpignan, France, ¹¹Lille University Hospital, Lille, France, ¹²CHU Nantes, Nantes, France, ¹³HEGP - APHP, Paris, France, ¹⁴Croix Saint Simon Hospital, Paris, France, ¹⁵Department of Neurology, Luxembourg Hospital Center, Luxembourg City, Luxembourg, ¹⁶Lyon University Hospital, Lyon, France, ¹⁷Grenoble Hospital (CH), Grenoble, France, ¹⁸Assistance Publique Hopitaux de Paris, Paris, France, ¹⁹Bichat-Claude Bernard, Universite de Paris, Paris, France, ²⁰Besançon University Hospital, Besançon, France, ²¹AP-HP, Bobigny, France, ²²Saint Quentin Hospital, Saint-Quentin, France, ²³Vannes Hospital (CH Bretagne Atlantique), Vannes, France, ²⁴Valenciennes Hospital (CH), Valenciennes, France, ²⁵Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Glucocorticoids (GCs) in combination with rituximab (RTX) or cyclophosphamide are the cornerstone of treatment for patients with severe granulomatosis with polyangiitis (GPA) and microscopic…
Abstract Number: 0857 • ACR Convergence 2023
Change in Albuminuria in Patients with ANCA-Associated Vasculitis Treated with Avacopan
Duvuru Geetha¹, Frank Cortazar², alexandre Karras³, Annette Bruchfeld⁴, Huibin Yue⁵, Peter Merkel⁶ and David Jayne⁷, ¹Johns Hopkins University, Baltimore, MD, ²New York Nephrology, Watervliet, NY, ³HEGP - APHP, Paris, France, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Urinary albumin:creatinine ratio (UACR) is an important biomarker of active glomerulonephritis, a common complication of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). In most glomerular…
Abstract Number: 1535 • ACR Convergence 2023
Epidemiology and Treatment Outcome of ANCA-associated Vasculitis in South Korea: A Nationwide, Population-based Cohort Study
Ji In Jung¹, Jun Won Park², Song Jihun³, Seulggie Choi², Sun Jae Park³, Sang Min Park² and Eun Young Lee⁴, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ²Seoul National University Hospital, Seoul, South Korea, ³Seoul National University Graduate School, Seoul, South Korea, ⁴Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: Previous studies on AAV have shown that the epidemiology and clinical features of GPA and MPA differ among countries. Considering their high mortality and…
Abstract Number: 1538 • ACR Convergence 2023
Large Vessel Involvement in Antineutrophil Cytoplasmic Antibody- Associated Vasculitis: A Single Center Experience over Two Decades
Mahmut Kaymakci¹, Mohanad Elfishawi¹, Hannah Langenfeld², Andrew Hanson², Cynthia Crowson¹, Melanie Bois¹, Umar Ghaffar¹, Ulrich Specks¹, Matthew Koster¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is currently categorized under the small vessel vasculitides and includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA),…
Abstract Number: 1553 • ACR Convergence 2023
Central Nervous System Involvement and Mimickers in ANCA Associated Vasculitis
Yeliz Yagiz Ozogul¹, Sinem Nihal Esatoglu², Murat Ozogul³, Osman Kizilkilic⁴, Yesim Ozguler⁵, Ugur Uygunoglu⁶, Vedat Hamuryudan² and Gulen Hatemi², ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Haydarpasa Numune Training and Research Hospital, Department of Radiology, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Radiology, Istanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Neurology, Istanbul, Turkey
Background/Purpose: Central nervous system (CNS) involvement is rare in ANCA associated vasculitis (AAV). On the other hand, AAV patients may develop complications or other conditions…
Abstract Number: 1584 • ACR Convergence 2023
Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study
Arielle Mendel¹, Hassan Behlouli², Evelyne Vinet¹, Jeffrey Curtis³ and Sasha Bernatsky², ¹McGill University Health Centre, Montréal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Infections during treatment of ANCA-associated vasculitis (AAV) lead to excess mortality. Trimethoprim sulfamethoxazole (TMP-SMX), recommended for pneumocystis jirovecii pneumonia (PJP) prophylaxis, has broad antimicrobial…
Abstract Number: 2375 • ACR Convergence 2023
Clinical Characteristics of ANCA-associated Vasculitis with High Levels of Serum Interleukin 7
Shoichi Fukui¹, Haruna Matsuo², Kanako Kojima³, Shota Kurushima¹, Tohru Michitsuji⁴, Yoshika Tsuji⁵, Toshimasa Shimizu³, Masataka Umeda³, Remi Sumiyoshi⁵, Takashi Igawa¹, Tomohiro Koga⁵, Shin-ya Kawashiri¹, Naoki Iwamoto¹, Tomoki Origuchi¹ and Atsushi Kawakami¹, ¹Nagasaki University, Nagasaki, Japan, ²Nagasaki University, Nagasaki City, Japan, ³Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Medical Sciences, Nagasaki, Japan, ⁵Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan
Background/Purpose: Interleukin 7 (IL-7) is a hematopoietic growth factor produced by stromal cells in the bone marrow and thymus, which is indispensable in maintaining immune…
Abstract Number: 2376 • ACR Convergence 2023
Eosinophil Activation as a Biomarker for Discriminating Active and Remission Phase in ANCA-Associated Vasculitis
Teppei Hashimoto¹, Kazuteru Noguchi², Yuko Minagawa², Takeo Abe², Masao Tamura², Tetsuya Furukawa¹, Naoto Azuma² and Kiyoshi Matsui¹, ¹Hyogo Medical University, Nishinomiya, Japan, ²Hyogo Medical University, School of Medicine, Nishinomiya, Japan
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a life-threatening disease requiring complex management due to a lack of suitable biomarkers. Elevated or persistently positive…
Abstract Number: 2379 • ACR Convergence 2023
A Real-World Descriptive Study of Renal Outcomes Among Patients with ANCA-Associated Vasculitis Initiating Remission Induction Therapy
Sam Oh¹, Sushmitha Inguva², Pallavi Rane² and Brian Tumminello³, ¹Amgen, Inc., South San Francisco, CA, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen, Inc., San Juan Capistrano, CA
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of rare autoimmune diseases characterized by inflammation and necrosis of small- to medium-sized blood vessels, commonly affecting the…
Abstract Number: 0682 • ACR Convergence 2023
Avacopan in ANCA-associated Vasculitis Received Intensified Induction Therapy with Cyclophosphamide Plus Rituximab – Retrospective Case Serial of 12 Patients
Gunter Assmann¹, Christoph Rittich¹, Frank Neumann², Udo Kellner³, Ryszard Turkiewicz⁴, Joerg Radermacher⁵, Peter Lamprecht⁶ and Björn Tampe⁷, ¹RUB University Hospital Minden - Rheumatology, Minden, Germany, ²Jose Carreras Center Saarland, Homburg, Germany, ³RUB University Hospital Minden - Pathology, Minden, Germany, ⁴RUB University Hospital Minden - Pulmonology, Minden, Germany, ⁵RUB University Hospital Minden - Nephrology, Minden, Germany, ⁶University Hospital Luebeck - Schleswig-Holstein, Luebeck, Germany, ⁷University Clinic department Goettingen - Nephrology, Goettingen, Germany
Background/Purpose: The orally administered C5a receptor inhibitor avacopan is approved for the therapy of ANCA-associated vasculitis (AAV) in combination with rituximab or cyclophosphamide and shows…
Abstract Number: 2380 • ACR Convergence 2023
Renal Survival Rate of ANCA-associated Vasculitis in Korea: A Nationwide Population-Based Study Using Claims Data
Chan-Bum Choi¹, Jung-Min Shin², Nayeon Choi³ and Soorack Ryu³, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, South Korea, ³Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea
Background/Purpose: ANCA-associated vasculitis (AAV) is a rare systemic autoimmune disease with varying reports of incidence rates and clinical manifestations. Renal involvement is one of the…
Abstract Number: 0684 • ACR Convergence 2023
Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Ulrich Specks¹, David Jayne² and Peter Merkel³, ¹Mayo Clinic, Rochester, MN, ²University of Cambridge, Cambridge, United Kingdom, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Although respiratory tract involvement in ANCA-associated vasculitis (AAV) is frequent and associated with increased mortality, studies focusing on diffuse alveolar hemorrhage (DAH) in AAV…
Abstract Number: 2385 • ACR Convergence 2023
Risk of Major Adverse Cardiovascular Events in ANCA-associated Vasculitis
Jon Idoate¹, Morgane Mourguet¹, Thomas Villeneuve¹, Grégoire Prevot¹, Laurent Guilleminault², Ribes David¹, Stan Faguer¹, Antoine Huart¹, Dominique Chauveau¹, Laurent Alric¹, Martin Michaud¹, Laurent Sailler¹, Sébastien De Almeida Chavez¹, Emmanuelle Mouchon¹, Olivier Lairez¹ and Gregory Pugnet³, ¹CHU Toulouse, Toulouse, France, ²Department of respiratory and allergic diseases, Toulouse University Hospital Center, Toulouse, France, ³CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France
Background/Purpose: The aim of this study was to investigate the risk of major adverse cardiovascular events (MACE) in patients with ANCA-associated vasculitis (AAV). Methods: We…
Abstract Number: 0685 • ACR Convergence 2023
Efficacy and Safety of Avacopan in Patients with ANCA-Associated Vasculitis Receiving Rituximab in a Phase 3 Trial
Duvuru Geetha¹, Anisha Dua², Huibin Yue³, Carlo Salvarani⁴, David Jayne⁵ and Peter Merkel⁶, ¹Johns Hopkins University, Baltimore, MD, ²Northwestern University, Chicago, IL, ³Amgen, Inc., Thousand Oaks, CA, ⁴Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: The randomized, double-blind, double-dummy, controlled Phase 3 ADVOCATE trial tested whether avacopan, an oral selective C5a receptor inhibitor approved for the treatment of ANCA-associated…
Abstract Number: 2492 • ACR Convergence 2023
The Impact of Neurologic Involvement in ANCA-Associated Vasculitis on Self-Reported Health-Related Quality of Life
Rula Hajj-Ali¹, Chao Zhang², Renee Borchin³, Jenn Gordon⁴, David Cuthbertson³, Carol McAlear⁵, Christine Yeung⁵, David Badenoch⁶, Cristina Burroughs³ and Peter Merkel⁵, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland, OH, ³University of South Florida, Tampa, FL, ⁴Vasculitis Patient Powered Research Network (VPPRN), Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Vasculitis Patient Powered Research Network (VPPRN), Los Angeles, CA
Background/Purpose: Neurologic involvement (NI) is a common manifestation in patients with ANCA-associated vasculitis (AAV) and can lead to chronic pain and disability. This project assessed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.